Topical corticosteroid phobia in patients with atopic eczema.
about
Emollients and moisturisers for eczemaHouse dust mite reduction and avoidance measures for treating eczemaOral evening primrose oil and borage oil for eczemaChinese herbal medicine for atopic eczemaChinese herbal medicine for atopic eczemaHouse dust mite reduction and avoidance measures for treating eczemaTopical pimecrolimus for eczemaDietary supplements for established atopic eczemaOral evening primrose oil and borage oil for atopic eczemaEvening primrose oil for atopic dermatitisA Review of Multidisciplinary Interventions in Atopic DermatitisConsensus Conference on Clinical Management of pediatric Atopic DermatitisPimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infantsThe Long-Term Course of Atopic Dermatitis.Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczemaEffect of emollients containing vegetable-derived lactobacillus in the treatment of atopic dermatitis symptoms: split-body clinical trial.Itching for a solutionNew approaches to topical therapy.The rationale behind topical vitamin d analogs in the treatment of psoriasis: where does topical calcitriol fit in?Evaluation of the atrophogenic potential of topical corticosteroids in pediatric dermatology patients.Topical corticosteroid misuse: the Indian scenario.Topical corticosteroid addiction and phobiaWhat's new in atopic dermatitis?Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life.The double benefits of educational programmes for patients with eczema.New treatments for atopic dermatitis.Treatment principles of atopic dermatitis.Pseudoceramide-containing physiological lipid mixture reduces adverse effects of topical steroidsExpert consensus: time for a change in the way we advise our patients to use topical corticosteroids.TOPICOP©: a new scale evaluating topical corticosteroid phobia among atopic dermatitis outpatients and their parentsGuidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies.Quality-of-life outcomes and measurement in childhood atopic dermatitisCurrent status of atopic dermatitis in Japan.Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells.Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement.Nonsteroidal treatment of atopic dermatitis in pediatric patients with a ceramide-dominant topical emulsion formulated with an optimized ratio of physiological lipids.Therapeutic potential of macrolide immunosuppressants in dermatology.Pimecrolimus for the treatment of inflammatory skin disease.
P2860
Q24186075-D56DE89C-60F4-49A6-A26C-4763948061DFQ24186585-8E533F8F-8A20-4CAB-8C16-E81DD95CC240Q24197709-B7912674-AB82-4ED4-B5ED-8817930AD073Q24198147-9A9870FB-D26D-4065-B225-141E4259961CQ24236700-6E70BB05-C13B-43CE-90E2-3F7A6A8DB5CAQ24239879-2CA3E2AD-EBBA-4CDA-9B9A-92B280A29BD7Q24243250-7B51179E-E56B-4B27-BF7D-6CEED28CB174Q24245966-DA63C766-BA11-4CF3-B2A7-AE87C753C5BBQ24250119-2F3C2759-3C5A-445D-AE3D-3B3DD63C4786Q24623031-79EA1292-F51B-4EE6-8D48-BAAA624EA622Q26799480-B64B5F37-9271-4FCA-BEC8-2F80B90FEF1FQ28071974-F38CBE0B-41F6-4002-A41C-B98BE4475424Q28086973-2A204CA5-6D1E-4F7E-9DE1-FF23917D46C2Q30234105-75852225-1C95-4255-83C1-2089AB845A96Q31149849-2E2191A3-5E0A-4813-8C2A-BE583C69BCF2Q33559959-5D651CAB-3656-4A7C-BC08-8FB4EE2EC95CQ33682076-C9C1B565-9B0E-4E80-8990-24432DEFAF7FQ33926979-38880DEF-54C1-4CEE-8718-A80C2B862771Q34106948-1404B650-5110-48CF-890F-F6BB1940D165Q34156429-B5C78C29-3798-470B-B1C6-585E232844DCQ34179621-2ADF4AC6-89F8-4158-B8F8-84B8DBBE0F5CQ34229138-B24ECD8B-6392-44A9-99C8-BDB60B4BB2F9Q34229151-4D44879F-584D-4A2B-A865-33DA5FCAC8A9Q34352747-EF1177F8-8A5F-4646-ACD2-EC6DBD6EE256Q34497913-EC9A36AB-A041-4C7B-A3A8-E91BB0B6943FQ34557008-337E479B-CE7C-4416-B941-1AAAB7847068Q34592295-65026D15-D8FE-4D14-8930-961CB67B969AQ34600248-6CF78393-2577-41DD-9D9C-1FBA164227A6Q34709971-383261DC-CD0E-44D4-BFDF-54641D290AD9Q34753936-380075E5-9B5B-4A1C-BF05-2E3886237711Q35022799-788B6B7D-85F1-4DE9-B7AF-58A8AC1115F6Q35077866-BDA4E7AB-4AF0-4FAD-8C4F-C6369B7A2435Q35106685-363A74B0-9B59-4D53-9693-359D3DA7933BQ35148180-067A43FA-D9B8-4EAA-88A2-CFB661234AC4Q35502677-768CE52C-E3EF-4CBE-8A0A-640FB4FB461DQ35568777-CF3A2E05-AB3E-46D3-91A9-DA41AD80CD92Q35573947-91F398CF-2C80-4148-B719-9E87C820D8CDQ35628612-8D8DBD06-662B-4A35-A375-DEB70EF840EDQ35680649-6B6B9DE4-DC11-4FB8-A3CE-4A8F61E31A08Q35688189-3F1DB1E4-C929-4D58-B31A-8A78CC601354
P2860
Topical corticosteroid phobia in patients with atopic eczema.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Topical corticosteroid phobia in patients with atopic eczema.
@en
Topical corticosteroid phobia in patients with atopic eczema.
@nl
type
label
Topical corticosteroid phobia in patients with atopic eczema.
@en
Topical corticosteroid phobia in patients with atopic eczema.
@nl
prefLabel
Topical corticosteroid phobia in patients with atopic eczema.
@en
Topical corticosteroid phobia in patients with atopic eczema.
@nl
P2093
P2860
P1476
Topical corticosteroid phobia in patients with atopic eczema.
@en
P2093
Charman CR
Williams HC
P2860
P304
P356
10.1046/J.1365-2133.2000.03473.X
P407
P577
2000-05-01T00:00:00Z